X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs NOVARTIS - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES NOVARTIS DIVIS LABORATORIES/
NOVARTIS
 
P/E (TTM) x 35.5 360.8 9.8% View Chart
P/BV x 6.9 31.8 21.7% View Chart
Dividend Yield % 0.6 1.4 45.1%  

Financials

 DIVIS LABORATORIES   NOVARTIS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
NOVARTIS
Mar-18
DIVIS LABORATORIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,142758 150.6%   
Low Rs533579 92.1%   
Sales per share (Unadj.) Rs146.6228.4 64.2%  
Earnings per share (Unadj.) Rs33.031.7 104.1%  
Cash flow per share (Unadj.) Rs38.432.8 117.2%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %1.21.5 79.8%  
Book value per share (Unadj.) Rs222.8297.1 75.0%  
Shares outstanding (eoy) m265.4724.69 1,075.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.72.9 195.2%   
Avg P/E ratio x25.321.1 120.3%  
P/CF ratio (eoy) x21.820.4 106.9%  
Price / Book Value ratio x3.82.2 167.0%  
Dividend payout %30.331.5 96.1%   
Avg Mkt Cap Rs m222,31816,505 1,347.0%   
No. of employees `00010.80.7 1,611.1%   
Total wages/salary Rs m4,5611,445 315.5%   
Avg. sales/employee Rs Th3,616.08,441.3 42.8%   
Avg. wages/employee Rs Th423.82,163.6 19.6%   
Avg. net profit/employee Rs Th814.91,173.1 69.5%   
INCOME DATA
Net Sales Rs m38,9155,639 690.1%  
Other income Rs m1,1341,718 66.0%   
Total revenues Rs m40,0497,357 544.4%   
Gross profit Rs m12,617-63 -20,187.4%  
Depreciation Rs m1,42525 5,632.0%   
Interest Rs m1355 24.1%   
Profit before tax Rs m12,3131,575 781.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,543792 447.6%   
Profit after tax Rs m8,770784 1,119.2%  
Gross profit margin %32.4-1.1 -2,925.2%  
Effective tax rate %28.850.3 57.3%   
Net profit margin %22.513.9 162.2%  
BALANCE SHEET DATA
Current assets Rs m45,3519,522 476.3%   
Current liabilities Rs m6,5073,296 197.4%   
Net working cap to sales %99.8110.4 90.4%  
Current ratio x7.02.9 241.3%  
Inventory Days Days12737 346.0%  
Debtors Days Days9528 334.7%  
Net fixed assets Rs m21,16046 45,998.9%   
Share capital Rs m531123 430.2%   
"Free" reserves Rs m58,6257,213 812.8%   
Net worth Rs m59,1567,336 806.3%   
Long term debt Rs m00-   
Total assets Rs m67,83211,105 610.8%  
Interest coverage x926.829.5 3,143.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.5 113.0%   
Return on assets %12.97.6 171.4%  
Return on equity %14.810.7 138.8%  
Return on capital %20.822.2 93.8%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35961 53,397.7%   
Fx outflow Rs m9,0423,630 249.1%   
Net fx Rs m23,317-3,570 -653.2%   
CASH FLOW
From Operations Rs m7,7591,610 481.9%  
From Investments Rs m-4,783687 -696.2%  
From Financial Activity Rs m-3,142-2,677 117.4%  
Net Cashflow Rs m-166-380 43.7%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.8 2.0 590.0%  
FIIs % 19.0 1.6 1,187.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 21.5 80.0%  
Shareholders   31,796 41,647 76.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Nov 21, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - FDC LTD. COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS